Benitec Biopharma reported net income of -$11.97M for the quarter ended Dec 2025. This income statement covers 27 quarters of results from Jun 2019 through Dec 2025, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 0.28M | 0.25M | 0.48M | 0.48M | 0.48M | 0.48M | 0.64M | 1.65M | 1.65M | 1.39M | 2.55M | 2.59M | 2.72M | 4.06M | 10.64M | 23.45M | 38.60M | 36.21M | 41.52M | 45.97M | |||||||
| Revenue & cost | |||||||||||||||||||||||||||
| Revenue | 0.00M | 0.00M | 0.03M | 0.05M | 0.01M | 0.05M | 0.01M | ||||||||||||||||||||
| Operating items | |||||||||||||||||||||||||||
| Research & DevelopmentR&D | 2.76M | 2.32M | 2.78M | 3.15M | 2.17M | 3.18M | 2.66M | 3.76M | 3.17M | 3.19M | 4.43M | 5.10M | 2.57M | 3.51M | 3.58M | 5.38M | 5.98M | 2.87M | 3.37M | 5.83M | |||||||
| Selling, General & AdministrativeSG&A | 1.03M | 1.54M | 2.04M | 1.71M | 1.34M | 1.55M | 1.92M | 1.86M | 1.23M | 1.37M | 1.55M | 1.82M | 1.58M | 2.04M | 2.21M | 5.42M | 4.21M | 6.97M | 6.43M | 7.54M | |||||||
| Other Operating ExpensesOther Opex | 0.01M | 0.00M | 0.01M | -0.11M | 0.00M | -0.00M | |||||||||||||||||||||
| Operating ExpensesOpex | 3.79M | 3.86M | 4.82M | 4.86M | 3.51M | 4.74M | 4.58M | 5.62M | 4.39M | 4.56M | 5.87M | 6.93M | 4.14M | 5.55M | 5.79M | 10.80M | 10.19M | 9.83M | 9.80M | 13.38M | |||||||
| Operating IncomeOp. Inc | -3.79M | -3.85M | -4.82M | -4.83M | -3.46M | -4.74M | -4.58M | -5.61M | -4.34M | -4.55M | -5.87M | -6.93M | -4.14M | -5.55M | -5.79M | -10.80M | -10.19M | -9.83M | -9.80M | -13.38M | |||||||
| EBIT | -3.79M | -3.85M | -4.82M | -4.83M | -3.46M | -4.74M | -4.58M | -5.61M | -4.34M | -4.55M | -5.87M | -6.93M | -4.14M | -5.55M | -5.79M | -10.80M | -10.19M | -9.83M | -9.80M | -13.38M | |||||||
| Non-operating items | |||||||||||||||||||||||||||
| Non Operating Investment Income | -0.00M | 0.02M | 0.02M | -0.02M | -0.01M | -0.00M | 0.00M | -0.00M | -0.00M | 0.00M | -0.00M | ||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | -0.00M | -0.00M | -0.00M | -0.01M | -0.01M | -0.01M | -0.01M | -0.01M | -0.01M | -0.01M | -0.01M | -0.01M | -0.00M | 0.92M | 0.60M | 0.82M | 0.82M | 1.04M | 1.01M | 1.39M | |||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.11M | -0.17M | -0.24M | 0.05M | 0.23M | -0.27M | -0.51M | 0.16M | -0.04M | -0.02M | -0.06M | 0.15M | -0.12M | -0.15M | 0.09M | 0.76M | 0.01M | -0.13M | -0.09M | 0.13M | |||||||
| Non Operating IncomeNon Op. Inc. | -0.12M | -0.15M | -0.22M | 0.01M | 0.18M | -0.33M | -0.51M | 0.20M | -0.06M | -0.11M | -0.08M | 0.13M | -0.14M | 0.83M | 0.73M | 1.25M | 0.83M | 1.03M | 0.84M | 1.54M | |||||||
| Net income details | |||||||||||||||||||||||||||
| EBT | -3.79M | -3.86M | -4.82M | -4.85M | -3.47M | -4.75M | -4.59M | -5.62M | -4.35M | -4.56M | -5.88M | -6.93M | -4.14M | -4.63M | -5.19M | -9.98M | -9.37M | -8.80M | -8.79M | -11.99M | |||||||
| Profit After TaxPAT | -3.93M | -4.00M | -5.04M | -4.82M | -3.51M | -5.02M | -5.09M | -5.41M | -4.40M | -4.70M | -5.95M | -6.80M | -4.28M | -4.78M | -5.16M | -9.55M | -9.38M | -8.93M | -8.96M | -11.97M | |||||||
| Income from Continuing OperationsIncome (Continuing) | -3.79M | -3.86M | -4.82M | -4.85M | -3.47M | -4.75M | -4.59M | -5.62M | -4.35M | -4.56M | -5.88M | -6.93M | -4.14M | -4.63M | -5.19M | -9.98M | -9.37M | -8.80M | -8.79M | -11.99M | |||||||
| Consolidated Net IncomeConsol Net Inc. | -3.79M | -3.86M | -4.82M | -4.85M | -3.47M | -4.75M | -4.59M | -5.62M | -4.35M | -4.56M | -5.88M | -6.93M | -4.14M | -4.63M | -5.19M | -9.98M | -9.37M | -8.80M | -8.79M | -11.99M | |||||||
| Income towards Parent CompanyParent Net Inc | -3.79M | -3.86M | -4.82M | -4.85M | -3.47M | -4.75M | -4.59M | -5.62M | -4.35M | -4.56M | -5.88M | -6.93M | -4.14M | -4.63M | -5.19M | -9.98M | -9.37M | -8.80M | -8.79M | -11.99M | |||||||
| Net Income towards Common StockholdersNet Income | -3.79M | -3.86M | -4.82M | -4.85M | -3.47M | -4.75M | -4.59M | -5.62M | -4.35M | -4.56M | -6.57M | -6.80M | -4.28M | -4.72M | -5.06M | -9.55M | -9.35M | -16.15M | -8.96M | -11.84M | |||||||
| Additional items | |||||||||||||||||||||||||||
| EPS (Basic) | -13.59 | -15.26 | -10.03 | -10.08 | -7.22 | -9.88 | -7.19 | -3.47 | -2.64 | -3.29 | -3.05 | -2.64 | -1.64 | -1.16 | -0.48 | -0.43 | -0.24 | -0.45 | -0.22 | -0.26 | |||||||
| EPS (Diluted) | -15.26 | -10.03 | -10.08 | -7.22 | -9.88 | -7.19 | -3.47 | -2.64 | -3.29 | -3.05 | -2.64 | -1.64 | -1.16 | -0.48 | -0.43 | -0.24 | -0.45 | -0.22 | -0.26 | ||||||||
| Shares Outstanding | 0.28M | 0.25M | 0.48M | 0.48M | 0.48M | 0.48M | 0.64M | 1.62M | 1.65M | 1.39M | 2.16M | 2.58M | 2.62M | 4.06M | 10.64M | 22.08M | 38.60M | 36.21M | 41.52M | 45.97M | |||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 0.25M | 0.48M | 0.48M | 0.48M | 0.48M | 0.64M | 1.62M | 1.65M | 1.39M | 2.16M | 2.58M | 2.62M | 4.06M | 10.64M | 22.08M | 38.60M | 36.21M | 41.52M | 45.97M | ||||||||
| EBITDA | -3.79M | -3.85M | -4.82M | -4.83M | -3.46M | -4.74M | -4.58M | -5.61M | -4.34M | -4.55M | -5.87M | -6.93M | -4.14M | -5.55M | -5.79M | -10.80M | -10.19M | -9.83M | -9.80M | -13.38M |